8 results about "Aldosterone Synthase Deficiency" patented technology

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The present application provides a salt of a triazine compound having an inhibitory action against aldosterone synthase, which is useful as a medicine, particularly a prophylactic or therapeutic agent for primary aldosteronism and the like, a crystal thereof, and a production method thereof. Specifically, the present application provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetylamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is a hydrobromide, a sulfate, a succinate, or a p-toluenesulfonate, or the like.

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthase inhibitor, and a preparation method therefor and the use thereof.  

Novel crystalline forms of baxdrostat, methods for producing the same, pharmaceutical compositions containing the crystalline form, and the production of aldosterone synthase inhibitors, as well as the use of the crystalline form in the production of pharmaceuticals for the treatment of hypertension, primary aldosteronism, and chronic kidney disease.

This invention relates to a method of treating heart failure with preserved ejection fraction (HFpEF) in a subject afflicted with HFpEF, the method comprising administering to the subject an aldosterone synthase inhibitor once per day in an amount effective to treat HFpEF in the subject. This invention also relates to a method of treating left ventricular diastolic dysfunction (LVDD) in a subject afflicted with LVDD, the method comprising administering to the subject an aldosterone synthase inhibitor once per day in an amount effective to treat LVDD in the subject.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

Disclosed are solid forms of an inhibitor of aldosterone synthase (ASi) having the formula The invention also relates to methods of making these solid forms, pharmaceutical compositions comprising these solid forms, and their use for medical conditions responsive to treatment with an inhibitor of aldosterone synthase.